DEGIRO Retailises European Online Brokerage With Zero Commission Trading on Top US and European Exchanges
18.11.2021 17:38:00 EET | Business Wire | Press release
Today, flatexDEGIRO (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR), Europe's largest and fastest-growing pan-European retail online broker announced the introduction of zero commission trading at DEGIRO, starting as of 22 November 2021. DEGIRO customers across Europe will thereby be able to trade without any commission over 5,000 US equities directly on the leading US exchanges NASDAQ and NYSE. Additionally, in the most important growth markets, France, Spain, Portugal and Italy, as well as in Sweden and Denmark, they will trade all ETFs commission-free as well as equities on the respective local Tier 1 exchanges, including Euronext Paris, and Lisbon, NASDAQ Stockholm, Bolsa de Madrid and Borsa Italia.
For the very first time, European retail investors will be able to trade at zero commission without having to compromise on quality, service, security, product choice or place of execution. flatexDEGIRO leverages its technological edge, its financial strengths and the scale of its market-leading pan-European online brokerage business to make this unique offer. The attractiveness and quality of the offer is expected to lead to an increasing revenue base and additional economies of scale which, together with optimised monetisation, should strongly improve flatexDEGIRO's operating profitability.
Frank Niehage, CEO of flatexDEGIRO: "With 'DEGIRO goes zero', we are changing the face of online brokerage in Europe. DEGIRO provides the lowest prices in the market with full cost transparency and no compromise on quality. We are now not only leading in platform and product but also in price. This will further increase the attractiveness of long-term investing and trading on our platform for millions of Europeans. No one interested in online brokerage should ever again feel the need to trade with brokers who supposedly charge no commissions but offer only intransparent and low-quality alternatives."
Muhamad Chahrour, CEO of DEGIRO and CFO of flatexDEGIRO: "It's as simple as that: for years, many so-called 'neo-brokers' claimed to offer zero commission trading - but at what costs? Clients were attracted to trade either highly risky CFDs or with market makers having intransparent product-pricing and scrutinised payments for order flow. No retail customer should ever again accept this specious trade-off. We promised to retailise capital market access - this is exactly what we now do with this revolutionary step. DEGIRO launches the first fair and most transparent zero commission retail brokerage, not relying on any payment for order flow."
Complex variable fee structures for external cost such as exchange fees and regulatory costs will be eliminated by a transparent and simple flat handling fee of as little as 50 Cents per transaction. DEGIRO also supports the best access to international equity markets with transparent and outstanding FX services and fees, including one of the lowest FX fees in the whole financial industry of just 0.25%.
About flatexDEGIRO AG
flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) operates one of the leading and fastest growing online brokerage businesses in Europe, executing millions of paperless securities transactions per annum. B2C customers in 18 European countries are serviced via the flatex and DEGIRO brands and offered a wide range of independent products at competitive pricing, based on a modern, in-house state-of-the-art technology.
With more than 1.25 million customers and over 75 million securities transactions in 2020, flatexDEGIRO is the largest retail online broker in Europe. In a time of bank consolidation, low interest rates and digitalization, the flatexDEGIRO Group is ideally positioned for further growth. Within the next five years, flatexDEGIRO aims to grow its customer base to 7-8 million customers, settling 250-350 million transactions per year - even in years with low volatility.
More information via https://www.flatexdegiro.com/en
|
Language: |
English |
|
|
Company: |
flatexDEGIRO AG |
|
|
Rotfeder-Ring 7 |
||
|
60327 Frankfurt / Main |
||
|
Germany |
||
|
Phone: |
+49 (0) 69 450001 0 |
|
|
E-mail: |
||
|
Internet: |
||
|
ISIN: |
DE000FTG1111 |
|
|
WKN: |
FTG111 |
|
|
Indices: |
SDAX |
|
|
Listed: |
Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Munich, Stuttgart, Tradegate Exchange |
|
|
EQS News ID: |
1250311 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118005880/en/
Contact information
Achim Schreck Tel. +49 (0) 69 450001 0
Head of IR & Corporate Communications achim.schreck@flatexdegiro.com
flatexDEGIRO AG
Rotfeder-Ring 7
D-60327 Frankfurt/Main
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom